Theravance Biopharma appoints James C. Kelly as Class I director

Theravance Biopharma, Inc.

James C. Kelly appointed to Board on April 11, 2023, as Class I director through 2024 AGM.
Kelly is Managing Director at Weiss Asset Management, joined in 2010.
He waived equity component of director compensation; standard indemnification agreement in place.
Board size increased to 10, will revert to 9 after Annual Meeting; Kelly deemed independent.
As of March 6, 2023, Kelly beneficially owned 0 ordinary shares of Theravance Biopharma.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James C. Kelly

Class I member of the Board

TBPH · Theravance Biopharma, Inc.

Effective: 2023-04-11
Filed: April 11, 2023, 7:59 PM ET

On April 11, 2023, James C. Kelly was appointed by the Board of Directors (the “Board”) of Theravance Biopharma, Inc. (the “Company”) to serve as a Class I member of the Board for a term expiring at the Company’s Annual General Meeting of Shareholders in 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James C. Kelly was appointed as Class I member of the Board at Theravance Biopharma, Inc..

Action: appointed
Role: Class I member of the Board

Exact text from the filing

On April 11, 2023, James C. Kelly was appointed by the Board of Directors (the “Board”) of Theravance Biopharma, Inc. (the “Company”) to serve as a Class I member of the Board for a term expiring at the Company’s Annual General Meeting of Shareholders in 2024.

View on SEC.gov

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-044043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.